Key facts
- OrsoBio’s last known valuation is $310.0M.
- It has raised $166.6M across 2 recorded rounds; the latest was Early Stage VC ($40.0M) in Aug 2024.
- Notable investors include Samsara BioCapital, Longitude Capital, Woodline Partners, Ascenta Capital, Eli Lilly — 8 tracked in total.
- OrsoBio has filed 2 Form Ds with the SEC since 2023, most recently Aug 2024 ($40.0M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for OrsoBio
Funding rounds
2 roundsAbout OrsoBio
Operator of a clinical-stage biopharmaceutical company intended to develop therapies for organ dysfunction. The company develops therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemia, enabling patients to boost the energy metabolism of their bodies.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2020
- Employees
- 15
- Website
- orsobio.com/
- Ownership
- Privately Held (backing)
OrsoBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OrsoBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OrsoBio in its N-PORT filings yet. We sweep new filings monthly.